MX2015015582A - Tratamiento de cancer con naltrexona. - Google Patents

Tratamiento de cancer con naltrexona.

Info

Publication number
MX2015015582A
MX2015015582A MX2015015582A MX2015015582A MX2015015582A MX 2015015582 A MX2015015582 A MX 2015015582A MX 2015015582 A MX2015015582 A MX 2015015582A MX 2015015582 A MX2015015582 A MX 2015015582A MX 2015015582 A MX2015015582 A MX 2015015582A
Authority
MX
Mexico
Prior art keywords
naltrexone
tlr9
present
subject
provides novel
Prior art date
Application number
MX2015015582A
Other languages
English (en)
Spanish (es)
Inventor
Dalgleish Angus
Allen Rachel
Original Assignee
Cancer Vaccine Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Vaccine Inst filed Critical Cancer Vaccine Inst
Publication of MX2015015582A publication Critical patent/MX2015015582A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2015015582A 2013-05-10 2014-05-12 Tratamiento de cancer con naltrexona. MX2015015582A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201308440A GB201308440D0 (en) 2013-05-10 2013-05-10 Therapeutic
PCT/GB2014/051439 WO2014181131A1 (en) 2013-05-10 2014-05-12 Treatment of cancer with naltrexone

Publications (1)

Publication Number Publication Date
MX2015015582A true MX2015015582A (es) 2016-08-11

Family

ID=48672126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015582A MX2015015582A (es) 2013-05-10 2014-05-12 Tratamiento de cancer con naltrexona.

Country Status (13)

Country Link
US (4) US9895438B2 (enExample)
EP (1) EP2994137B1 (enExample)
JP (1) JP6346269B2 (enExample)
KR (1) KR102162038B1 (enExample)
CN (1) CN105451740B (enExample)
AU (1) AU2014264445B2 (enExample)
BR (1) BR112015028269A2 (enExample)
CA (1) CA2912203C (enExample)
GB (1) GB201308440D0 (enExample)
IL (1) IL242533B (enExample)
MX (1) MX2015015582A (enExample)
RU (1) RU2686325C2 (enExample)
WO (1) WO2014181131A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410216D0 (en) * 2014-06-09 2014-07-23 Cancer Vaccine Inst Therapeutic
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
CN111050801B (zh) * 2017-03-28 2023-03-28 Ldn制药有限公司 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂
WO2019055597A1 (en) * 2017-09-13 2019-03-21 National Tuberous Sclerosis Association, Inc. Methods and compositions for the treatment of tsc
CA3113895A1 (en) * 2018-11-01 2020-05-07 Faron Pharmaceuticals Oy Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
WO2020178446A1 (en) * 2019-03-06 2020-09-10 LDN Pharma Limited Method of monitoring treatment
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
AU2022211609A1 (en) * 2021-01-25 2023-07-27 LDN Pharma Limited Naltrexone compositions
CN114836529B (zh) * 2022-03-30 2023-05-30 唐颢 Ogfr基因或其编码的蛋白在心肌损伤辅助诊断及治疗中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689332A (en) * 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US6136780A (en) * 1996-03-29 2000-10-24 The Penn State Research Foundation Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6288074B1 (en) * 1998-11-17 2001-09-11 Bernard Bihari Method of treating lymphoproliferative syndrome
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
CN103405431B (zh) * 2002-05-17 2016-04-13 台湾J药品有限公司 阿片和阿片样化合物及其用途
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
GB0509052D0 (en) 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20090191185A1 (en) * 2006-04-26 2009-07-30 The Uab Research Foundation Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling
WO2011009015A1 (en) * 2009-07-16 2011-01-20 Mallinckrodt Inc. (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
EP2593095B1 (en) 2010-07-16 2019-03-27 Mallinckrodt LLC (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
GB201410216D0 (en) * 2014-06-09 2014-07-23 Cancer Vaccine Inst Therapeutic
GB201704909D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I

Also Published As

Publication number Publication date
CA2912203A1 (en) 2014-11-13
EP2994137A1 (en) 2016-03-16
GB201308440D0 (en) 2013-06-19
US20220040295A1 (en) 2022-02-10
BR112015028269A2 (pt) 2017-07-25
IL242533B (en) 2020-10-29
WO2014181131A1 (en) 2014-11-13
NZ714999A (en) 2021-05-28
AU2014264445A1 (en) 2016-01-07
KR20160032013A (ko) 2016-03-23
CN105451740A (zh) 2016-03-30
KR102162038B1 (ko) 2020-10-06
JP6346269B2 (ja) 2018-06-20
RU2686325C2 (ru) 2019-04-25
CA2912203C (en) 2021-08-17
JP2016524602A (ja) 2016-08-18
CN105451740B (zh) 2019-07-19
EP2994137B1 (en) 2022-12-14
US20160106832A1 (en) 2016-04-21
US20180207263A1 (en) 2018-07-26
AU2014264445B2 (en) 2019-08-15
RU2015152785A (ru) 2017-06-16
US9895438B2 (en) 2018-02-20
US20230390388A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
MX2015015582A (es) Tratamiento de cancer con naltrexona.
IL310023B2 (en) Compounds interacting with the ras superfamily for the treatment of cancer, inflammation, ras pathologies and fibrotic diseases
MX2021005471A (es) Particulas inmunomodificadoras para el tratamiento de la inflamacion.
PH12019501959A1 (en) Therapeutic rna
TN2017000032A1 (en) Protein kinase c inhibitors and methods of their use
EA201591977A1 (ru) Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
NZ749218A (en) Androgen receptor modulator and uses thereof
MX379463B (es) Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2013006398A (es) Inhibidores de f1f0-atpasas de tipo piridonilguanidina y usos terapeúticos.
NZ739867A (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2015011671A (es) Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis.
PH12016501407A1 (en) Treatment of neoplasia
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
EP4219458A3 (en) Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.
PH12016501347A1 (en) Filters for infusion sets
PH12019502314A1 (en) Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
IN2013MU02469A (enExample)
EA201890489A1 (ru) Car макрофагов (moto-car) в иммунотерапии
UY36563A (es) Metodo para mejorar la terapia con agonista del receptor gabab